Form 8-K - Current report:
SEC Accession No. 0001104659-25-030583
Filing Date
2025-04-01
Accepted
2025-04-01 16:30:32
Documents
16
Period of Report
2025-04-01
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510381d1_8k.htm   iXBRL 8-K 53959
2 EXHIBIT 99.1 tm2510381d1_ex99-1.htm EX-99.1 377334
3 EXHIBIT 99.2 tm2510381d1_ex99-2.htm EX-99.2 186366
4 EXHIBIT 99.3 tm2510381d1_ex99-3.htm EX-99.3 476360
  Complete submission text file 0001104659-25-030583.txt   1396716

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cara-20250401.xsd EX-101.SCH 3038
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cara-20250401_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cara-20250401_pre.xml EX-101.PRE 22374
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2510381d1_8k_htm.xml XML 3688
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 25800225
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)